The introduction of Retatrutide ZPHC, at a dosage of 120mg, is generating considerable excitement within the medical community. This novel dual GIP and GLP-1 target medication appears to provide impressive improvements in weight loss compared to current therapies. Early patient studies have demonstrated substantial reductions in body mass , potenti